Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Sundance: Telling three parallel stories at various points in time, Stanton's film spans 47,000 years in search of a single ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on December 19, 2025, according to a report published in TheFly. On December 17, 2025, JPMorgan ...

Leaders don’t fail from complexity overload. They fail from pretending it’s simple, then engineering systems that move ...

Q4 2025 Earnings Call January 22, 2026 5:00 PM ESTCompany ParticipantsJohn Pitzer - Corporate Vice President of Corporate ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

Information pervades the universe, yet means nothing. Meaning emerged when matter organized into systems that could ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.